Your browser doesn't support javascript.
Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey.
Shapiro Ben David, Shirley; Shamir-Stein, Na'ama; Baruch Gez, Sharon; Lerner, Uri; Rahamim-Cohen, Daniella; Ekka Zohar, Anat.
  • Shapiro Ben David S; Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel. Electronic address: shapira_sr@mac.org.il.
  • Shamir-Stein N; Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Baruch Gez S; Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Lerner U; Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Rahamim-Cohen D; Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Ekka Zohar A; Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel.
Clin Immunol ; 232: 108860, 2021 11.
Article in English | MEDLINE | ID: covidwho-1433070
ABSTRACT

BACKGROUND:

Since July 13, 2021, a third SARS-CoV-2 vaccine BNT162b2 was approved in Israel to immunocompromised and seniors 60 years of age or older. We aimed to evaluate vaccine's reactogenicity.

METHODS:

A retrospective cohort, using electronic surveys sent to booster vaccine recipients, during July 20-August 10, 2021.

RESULTS:

17,820 participated in the survey, with a response rate of 30.2%. 3195 (17.9%) were immunocompromised. Fatigue, myalgia and fever were the most frequent systemic side effects reported (19.6%, 9.2% and 8.1% respectively among immunocompromised; 21.3%, 9.9% and 9.2% respectively among seniors). 67.3% of immunocompromised and 62% of seniors reported experiencing a better or a similar response to the third dose, compared to the second.

CONCLUSIONS:

Local and systemic reactions after third BNT162b2 vaccine, reported by immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. These findings may aid promoting confidence among vaccine providers and recipients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA, Messenger / Immunocompromised Host / COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA, Messenger / Immunocompromised Host / COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article